Conduit Pharmaceuticals Inc. (NASDAQ:CDT) — Market Cap & Net Worth
Market Cap & Net Worth: Conduit Pharmaceuticals Inc. (CDT)
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has a market capitalization of $2.71 Million ($2.71 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29711 globally and #6049 in its home market, demonstrating a -67.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Conduit Pharmaceuticals Inc.'s stock price $0.20 by its total outstanding shares 13693866 (13.69 Million). Also see CDT current and non-current assets for a full breakdown of the balance sheet.
Conduit Pharmaceuticals Inc. Market Cap History: 2022 to 2026
Conduit Pharmaceuticals Inc.'s market capitalization history from 2022 to 2026. Data shows change from $140.36 Million to $2.71 Million (-58.33% CAGR). Also see Conduit Pharmaceuticals Inc. (CDT) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Conduit Pharmaceuticals Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #865 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2765 of 3165 |
Weight: Conduit Pharmaceuticals Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Conduit Pharmaceuticals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Conduit Pharmaceuticals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Conduit Pharmaceuticals Inc. share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Conduit Pharmaceuticals Inc.'s market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $939.40K | $922.22 Million | -$17.80 Million | 0.00x | N/A |
| 2025 | $17.53 Million | $2.72 Billion | -$39.22 Million | 0.01x | N/A |
Competitor Companies of CDT by Market Capitalization
Companies near Conduit Pharmaceuticals Inc. in the global market cap rankings as of September 18, 2026. Review Conduit Pharmaceuticals Inc. (CDT) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Conduit Pharmaceuticals Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Conduit Pharmaceuticals Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, Conduit Pharmaceuticals Inc.'s market cap moved from $140.36 Million to $ 2.71 Million, with a yearly change of -58.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.71 Million | -84.53% |
| 2025 | $17.53 Million | +1765.89% |
| 2024 | $939.40K | -98.49% |
| 2023 | $62.31 Million | -55.61% |
| 2022 | $140.36 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Conduit Pharmaceuticals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.71 Million USD |
| MoneyControl | $2.71 Million USD |
| MarketWatch | $2.71 Million USD |
| marketcap.company | $2.71 Million USD |
| Reuters | $2.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more